$9.46
0.000.00%
At close: -
$9.46
0.000.00%
After Hours: Apr 25, 4:00 PM EDT
Comments
Loading...
Elanco Animal Health Analyst Ratings and Price Targets | NYSE:ELAN | Benzinga
Elanco Animal Health Inc has a consensus price target of $15.27 based on the ratings of 11 analysts. The high is $20 issued by Morgan Stanley on November 15, 2022. The low is $9 issued by Goldman Sachs on April 25, 2023. The 3 most-recent analyst ratings were released by Stifel, Piper Sandler, and UBS on April 14, 2025, March 6, 2025, and February 26, 2025, respectively. With an average price target of $14 between Stifel, Piper Sandler, and UBS, there's an implied 47.99% upside for Elanco Animal Health Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Piper Sandler
UBS
Morgan Stanley
Barclays
1calculated from analyst ratings
Analyst Ratings for Elanco Animal Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/14/2025 | Buy Now | 37.42% | Stifel | Jonathan Block71% | $15 → $13 | Maintains | Buy | Get Alert |
| 03/06/2025 | Buy Now | 26.85% | Piper Sandler | David Westenberg59% | $16 → $12 | Maintains | Neutral | Get Alert |
| 02/26/2025 | Buy Now | 79.7% | UBS | Andrea Alfonso9% | $18 → $17 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 37.42% | Morgan Stanley | Erin Wright76% | $14 → $13 | Maintains | Equal-Weight | Get Alert |
| 02/26/2025 | Buy Now | 58.56% | Stifel | Jonathan Block71% | $16 → $15 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 100.85% | Barclays | Balaji Prasad53% | $20 → $19 | Maintains | Overweight | Get Alert |
| 02/21/2025 | Buy Now | 69.13% | Stifel | Jonathan Block71% | $18 → $16 | Maintains | Buy | Get Alert |
| 01/29/2025 | Buy Now | 47.99% | Morgan Stanley | Erin Wright76% | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 01/07/2025 | Buy Now | 90.27% | Stifel | Jonathan Block71% | $20 → $18 | Maintains | Buy | Get Alert |
| 12/09/2024 | Buy Now | 90.27% | UBS | Andrea Alfonso9% | → $18 | Initiates | → Buy | Get Alert |
| 12/02/2024 | Buy Now | 47.99% | Leerink Partners | Daniel Clark32% | → $14 | Initiates | → Market Perform | Get Alert |
| 11/08/2024 | Buy Now | 111.42% | Barclays | Balaji Prasad53% | $19 → $20 | Maintains | Overweight | Get Alert |
| 10/28/2024 | Buy Now | 100.85% | Barclays | Balaji Prasad53% | $22 → $19 | Maintains | Overweight | Get Alert |
| 09/23/2024 | Buy Now | 132.56% | Barclays | Balaji Prasad53% | $21 → $22 | Maintains | Overweight | Get Alert |
| 09/19/2024 | Buy Now | 111.42% | Stifel | Jonathan Block71% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2024 | Buy Now | 58.56% | Morgan Stanley | Erin Wright76% | $17 → $15 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 07/01/2024 | Buy Now | 69.13% | Piper Sandler | David Westenberg59% | $19 → $16 | Maintains | Neutral | Get Alert |
| 06/28/2024 | Buy Now | 121.99% | Barclays | Balaji Prasad53% | $23 → $21 | Maintains | Overweight | Get Alert |
| 05/13/2024 | Buy Now | 100.85% | Piper Sandler | David Westenberg59% | $18 → $19 | Reiterates | Neutral → Neutral | Get Alert |
| 05/09/2024 | Buy Now | 143.13% | Barclays | Balaji Prasad53% | $19 → $23 | Maintains | Overweight | Get Alert |
| 03/12/2024 | Buy Now | 90.27% | Piper Sandler | David Westenberg59% | $12 → $18 | Reiterates | Neutral → Neutral | Get Alert |
| 02/27/2024 | Buy Now | 47.99% | Goldman Sachs | Nathan Rich43% | $12.5 → $14 | Maintains | Sell | Get Alert |
| 02/27/2024 | Buy Now | 79.7% | Morgan Stanley | Erin Wright76% | $16 → $17 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | 100.85% | Barclays | Balaji Prasad53% | $18 → $19 | Maintains | Overweight | Get Alert |
| 01/17/2024 | Buy Now | 32.14% | Goldman Sachs | Nathan Rich43% | $10 → $12.5 | Maintains | Sell | Get Alert |
| 01/05/2024 | Buy Now | 111.42% | Stifel | Jonathan Block71% | $13 → $20 | Upgrade | Hold → Buy | Get Alert |
| 12/19/2023 | Buy Now | 79.7% | Jefferies | Glen Santangelo51% | → $17 | Initiates | → Buy | Get Alert |
| 12/15/2023 | Buy Now | 69.13% | Morgan Stanley | Erin Wright76% | → $16 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/07/2023 | Buy Now | 37.42% | Stifel | Jonathan Block71% | $12 → $13 | Maintains | Hold | Get Alert |
| 11/13/2023 | Buy Now | 26.85% | Piper Sandler | David Westenberg59% | $11 → $12 | Maintains | Neutral | Get Alert |
| 11/08/2023 | Buy Now | 69.13% | Morgan Stanley | Erin Wright76% | $17 → $16 | Maintains | Equal-Weight | Get Alert |
| 10/30/2023 | Buy Now | 26.85% | Stifel | Jonathan Block71% | $13 → $12 | Maintains | Hold | Get Alert |
| 08/14/2023 | Buy Now | 37.42% | Piper Sandler | David Westenberg59% | $9 → $13 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | 0.42% | Goldman Sachs | Nathan Rich43% | $8.5 → $9.5 | Maintains | Sell | Get Alert |
| 08/08/2023 | Buy Now | 0.42% | Goldman Sachs | Nathan Rich43% | $8.5 → $9.5 | Maintains | Sell | Get Alert |
| 04/26/2023 | Buy Now | -4.86% | Goldman Sachs | Nathan Rich43% | $10.5 → $9 | Maintains | Sell | Get Alert |
| 04/25/2023 | Buy Now | -4.86% | Goldman Sachs | Nathan Rice58% | $10.5 → $9 | Maintains | Sell | Get Alert |
| 04/20/2023 | Buy Now | 47.99% | Barclays | Balaji Prasad53% | → $14 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 02/22/2023 | Buy Now | 47.99% | Barclays | Balaji Prasad53% | $18 → $14 | Maintains | Equal-Weight | Get Alert |
| 01/30/2023 | Buy Now | 100.85% | Morgan Stanley | Erin Wright76% | $20 → $19 | Maintains | Equal-Weight | Get Alert |
| 11/15/2022 | Buy Now | 111.42% | Morgan Stanley | Joseph Moore68% | $21 → $20 | Maintains | Equal-Weight | Get Alert |
| 11/14/2022 | Buy Now | 58.56% | Piper Sandler | David Westenberg59% | $21 → $15 | Maintains | Neutral | Get Alert |
| 11/09/2022 | Buy Now | 26.85% | Goldman Sachs | Nathan Rich43% | $19 → $12 | Maintains | Sell | Get Alert |
| 10/17/2022 | Buy Now | 111.42% | JP Morgan | Chris Schott59% | $24 → $20 | Maintains | Neutral | Get Alert |
| 10/07/2022 | Buy Now | 121.99% | Morgan Stanley | Joseph Moore68% | $22 → $21 | Maintains | Equal-Weight | Get Alert |
| 09/12/2022 | Buy Now | 90.27% | Barclays | Balaji Prasad53% | $32 → $18 | Maintains | Equal-Weight | Get Alert |
| 08/18/2022 | Buy Now | 132.56% | Morgan Stanley | Erin Wright76% | $37 → $22 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/17/2022 | Buy Now | 121.99% | Piper Sandler | David Westenberg59% | $22 → $21 | Maintains | Neutral | Get Alert |
| 08/16/2022 | Buy Now | — | JP Morgan | Chris Schott59% | — | Downgrade | Overweight → Neutral | Get Alert |
| 07/21/2022 | Buy Now | 100.85% | Goldman Sachs | Nathan Rich43% | $32 → $19 | Downgrade | Buy → Sell | Get Alert |
| 07/18/2022 | Buy Now | 238.27% | JP Morgan | Chris Schott59% | $37 → $32 | Maintains | Overweight | Get Alert |
| 07/12/2022 | Buy Now | 132.56% | Piper Sandler | David Westenberg59% | → $22 | Initiates | → Neutral | Get Alert |
| 06/24/2022 | Buy Now | 132.56% | Stifel | Jonathan Block71% | $30 → $22 | Maintains | Hold | Get Alert |
| 05/19/2022 | Buy Now | 238.27% | Goldman Sachs | Nathan Rich43% | $37 → $32 | Maintains | Buy | Get Alert |
| 05/17/2022 | Buy Now | 291.12% | Morgan Stanley | Erin Wright76% | $40 → $37 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Elanco Animal Health (ELAN) stock?
The latest price target for Elanco Animal Health (NYSE:ELAN) was reported by Stifel on April 14, 2025. The analyst firm set a price target for $13.00 expecting ELAN to rise to within 12 months (a possible 37.42% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Elanco Animal Health (ELAN)?
The latest analyst rating for Elanco Animal Health (NYSE:ELAN) was provided by Stifel, and Elanco Animal Health maintained their buy rating.
When was the last upgrade for Elanco Animal Health (ELAN)?
The last upgrade for Elanco Animal Health Inc happened on January 5, 2024 when Stifel raised their price target to $20. Stifel previously had a hold for Elanco Animal Health Inc.
When was the last downgrade for Elanco Animal Health (ELAN)?
The last downgrade for Elanco Animal Health Inc happened on September 19, 2024 when Morgan Stanley changed their price target from $17 to $15 for Elanco Animal Health Inc.
When is the next analyst rating going to be posted or updated for Elanco Animal Health (ELAN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elanco Animal Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elanco Animal Health was filed on April 14, 2025 so you should expect the next rating to be made available sometime around April 14, 2026.
Is the Analyst Rating Elanco Animal Health (ELAN) correct?
While ratings are subjective and will change, the latest Elanco Animal Health (ELAN) rating was a maintained with a price target of $15.00 to $13.00. The current price Elanco Animal Health (ELAN) is trading at is $9.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
